Anavex Life Sciences Corp (AVXL)

[falconer66a]

Yes, Early Thinking About Two Anavex Questions

Two significant clinical determinations must be made.

1. Will Anavex 2-73 restoration of neuron architecture and function persist after a reviving initial treatment period without continued dosings?

If treatment must be chronic, continuing, that has economic implications for health insurance companies and patients; along with persisting revenue streams to Anavex Life Sciences Corp.

2. Will Anavex 2-73 demonstrate central nervous system disease prophylaxis, prevention before major disease symptoms occur?

If so, there would likely be widespread, perhaps universal prescription of the drug to people when they attain late middle age. Profound financial implications for all health care stakeholders (and for Anavex Life Sciences Corp).

The greater question is the latter, the prospect of Anavex prophylactic use against any number of CNS diseases and conditions.

We’ll all be watching these things in the coming years.